Xilio Therapeutics (XLO) Non Operating Income (2021 - 2026)
Xilio Therapeutics (XLO) reported Non Operating Income of $4.6 million for Q1 2026, up 682.08% on a YoY basis from $586000.0 in Q1 2025, and down 79.35% sequentially from $22.2 million in Q4 2025.
Xilio Therapeutics (XLO) Non Operating Income (2021 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 6 years of Non Operating Income data on file, last reported at $4.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 682.08% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (up 314.04% YoY), and the FY2025 full-year result was $6.9 million, up 196.71% from the prior year.
- Non Operating Income fell to $4.6 million in Q1 2026, from $22.2 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $22.2 million in Q4 2025 to a low of -$14.4 million in Q3 2025.
- A 5-year average of $1.0 million and a median of $586000.0 in 2025 frame the typical range for Non Operating Income.
- Peak annual rise in Non Operating Income reached 4041.04% in 2025, while the deepest fall reached 2035.04% in 2025.
- Tracing XLO's Non Operating Income over 5 years: stood at $701000.0 in 2022, then tumbled by 32.24% to $475000.0 in 2023, then advanced by 12.84% to $536000.0 in 2024, then surged by 4041.04% to $22.2 million in 2025, then plunged by 79.35% to $4.6 million in 2026.
- Business Quant data shows XLO's Non Operating Income at $4.6 million in Q1 2026, $22.2 million in Q4 2025, and -$14.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -8.59 Mn |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | 4.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.58 Mn |
| Dec 31, 2025 | 22.20 Mn |
| Sep 30, 2025 | -14.36 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | 586,000.00 |
| Dec 31, 2024 | 536,000.00 |
| Sep 30, 2024 | 742,000.00 |
| Jun 30, 2024 | 779,000.00 |
| Mar 31, 2024 | 284,000.00 |
| Dec 31, 2023 | 475,000.00 |
| Sep 30, 2023 | 613,000.00 |
| Jun 30, 2023 | 761,000.00 |
| Mar 31, 2023 | 880,000.00 |
| Dec 31, 2022 | 701,000.00 |
| Sep 30, 2022 | 416,000.00 |
| Jun 30, 2022 | -61,000.00 |
| Mar 31, 2022 | -129,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Sep 30, 2021 | -290,000.00 |
| Jun 30, 2021 | -174,000.00 |